BriaCell Therapeutics Corp. (TSX: BCT.TO) AI-Powered Stock Analysis
See how BriaCell Therapeutics Corp. scores across key metrics like financial growth, valuation, and market position on the TSX, using AI-driven evaluation.
BCT.TO●TSX
HealthcareBiotechnology
$4.82
$0.74(13.31%)
Canadian Market opens in 14h 46m
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continuously improving this model to increase accuracy and performance.Read our Full DisclaimerBriaCell Therapeutics Corp. (TSX: BCT.TO) Stock Overall Grade
BriaCell Therapeutics Corp.'s grade for its TSX listing, based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to BriaCell Therapeutics Corp.'s overall TSX stock rating.
Forecast
C+Score
57/100Financial Growth
CScore
40/100Fundamental Growth
BScore
61/100Key Ratios
C+Score
55/100Sector Comparison
B+Score
75/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
98/100Analyst Consensus
C+Score
50/100BriaCell Therapeutics Corp. (TSX: BCT.TO) AI-Powered Stock Analysis
On the TSX, BCT.TO demonstrates Good performance with an overall Forecast Score of 57/100 (C+), reflecting weak confidence in its potential. Financial Growth (40/100, C) and Fundamental Growth (61/100, B) highlight its stability, while Key Ratios (55/100, C+) and Sector Comparison (75/100, B+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (98/100, A+), the TSX-listed stock shows competitive strength. Analyst Consensus (50/100, C+) suggests High divergence in outlook.(TSX: BCT.TO) Component Analysis Explained
Understand the key factors behind each BriaCell Therapeutics Corp. (TSX: BCT.TO) stock grade, including financials, comparisons, and forecasts.